Billiontoone (NASDAQ:BLLN) Insider Sells 35,112 Shares

Billiontoone, Inc. (NASDAQ:BLLN) insider Thomas Lynch sold 35,112 shares of the firm’s stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $110.33, for a total transaction of $3,873,906.96. Following the completion of the transaction, the insider directly owned 700 shares in the company, valued at $77,231. This trade represents a 98.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Billiontoone Stock Down 1.9%

Shares of NASDAQ:BLLN traded down $2.06 during midday trading on Monday, hitting $103.86. 412,675 shares of the company’s stock were exchanged, compared to its average volume of 596,416. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.69 and a quick ratio of 11.31. Billiontoone, Inc. has a 12 month low of $61.96 and a 12 month high of $150.44. The company has a market cap of $4.90 billion and a PE ratio of 151.31. The stock has a 50 day moving average price of $109.42 and a 200-day moving average price of $97.24.

Billiontoone (NASDAQ:BLLN) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.15. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%.The business had revenue of $109.45 million during the quarter. On average, sell-side analysts anticipate that Billiontoone, Inc. will post 0.83 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. JPMorgan Chase & Co. dropped their price objective on Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a research note on Thursday, August 6th. Canaccord Genuity Group started coverage on shares of Billiontoone in a research note on Wednesday, September 2nd. They issued a “buy” rating and a $120.00 target price for the company. Wall Street Zen downgraded shares of Billiontoone from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Guggenheim began coverage on shares of Billiontoone in a research report on Monday, June 29th. They set a “buy” rating and a $125.00 price target on the stock. Finally, Weiss Ratings raised shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Seven analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $125.88.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Integrated Wealth Concepts LLC purchased a new stake in shares of Billiontoone during the 2nd quarter valued at $29,000. MCF Advisors LLC raised its stake in shares of Billiontoone by 330.8% during the 2nd quarter. MCF Advisors LLC now owns 448 shares of the company’s stock worth $54,000 after purchasing an additional 344 shares during the period. Thrive Wealth Management LLC purchased a new position in shares of Billiontoone in the 2nd quarter worth about $240,000. Caitong International Asset Management Co. Ltd bought a new stake in Billiontoone in the fourth quarter worth about $230,000. Finally, Jasper Ridge Partners L.P. purchased a new stake in Billiontoone in the second quarter worth $615,000.

About Billiontoone

BillionToOne, Inc is a molecular diagnostics company that develops blood-based tests designed to provide genetic and health information from small amounts of biological material. The company’s technology uses its proprietary quantitative counting template approach to improve the accuracy and sensitivity of molecular testing.

The company’s primary offerings include UNITY, a portfolio of prenatal genetic tests. These services support screening for chromosomal conditions, single-gene disorders and carrier status, and are designed to help healthcare providers assess fetal and maternal genetic risks using a maternal blood sample.